Volume 20 Issue 9
Sep.  2022
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2022  >  20(9): 1462-1465
GUO Ying, GAO Tian-hui, ZHAO Meng-yang, ZHOU Li-qin, LIU Shan-shan. Study on the relationship between lymphocyte subsets, cytokines and immune efficacy in advanced non-small cell lung cancer[J]. Chinese Journal of General Practice, 2022, 20(9): 1462-1465. doi: 10.16766/j.cnki.issn.1674-4152.002623
Citation: GUO Ying, GAO Tian-hui, ZHAO Meng-yang, ZHOU Li-qin, LIU Shan-shan. Study on the relationship between lymphocyte subsets, cytokines and immune efficacy in advanced non-small cell lung cancer[J]. Chinese Journal of General Practice, 2022, 20(9): 1462-1465. doi: 10.16766/j.cnki.issn.1674-4152.002623
shu

Study on the relationship between lymphocyte subsets, cytokines and immune efficacy in advanced non-small cell lung cancer

doi: 10.16766/j.cnki.issn.1674-4152.002623

  • Department of Oncology, Henan University People's Hospital, Zhengzhou, Henan 450003, China

Funds:

 162102310020

  • Received Date: 2022-11-15
    Available Online: 2022-11-29
    Abstract
  •   Objective  Immuno-checkpoint inhibitors significantly change the treatment prospects for non-small cell lung cancer. PD-L1, as a biomarker of immunotherapy, is extensively used in clinical settings, but some defects remain in its application. This study aimed to further explore the predictive effect of serum-related markers in clinical practice.  Methods  We retrospectively collected 48 cases of advanced non-small cell lung cancer patients receiving immunotherapy in Henan Provincial People's Hospital from 2019 to June 2021. Fasting peripheral blood was taken before treatment and after 4 cycles of treatment to detect the levels of cytokines and lymphocyte subsets. After four cycles, according to the efficacy (complete response, CR; partial response, PR; stable disease, SD; progressive disease, PD), it was divided into a control group (CR+PR+SD) for a total of 36 cases and an ineffective group (PD) for 12 cases. The changes in level after treatment between the two groups and the relationship with efficacy were compared.  Results  After the four cycles of immunotherapy treatment, lymphocyte levels, total T lymphocyte levels, and CD4+ T lymphocyte levels in the control group were significantly higher than those in the ineffective group [(1 648±564) μL vs. (1 098±581) μL; (1 121±388) μL vs. (651±368) μL; 540(367, 799) μL vs. 245(125, 411) μL, all P < 0.05]. The count level of T cells was significantly negatively correlated with tumor progression, and a higher T cell expression level corresponded with better progression-free survival (PFS). Conversely, the high expression of IL-4 and IL-6 was significantly positively correlated with tumor progression, and PFS was worse.  Conclusion  The lymphocyte subgroups and expression levels of cytokines are closely related to the efficacy of patients with advanced non-small cell lung cancer. They can be used as predictors of the efficacy of immunotherapy for advanced non-small cell lung cancer.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer statistics, 2021[J]. CA Can J Clin, 2021, 71(1): 7-33. doi: 10.3322/caac.21654
    [2]
    谈艳芳, 刘利洪, 孙家祥. NSE、SCC-Ag、CEA、CYFRA21-1联合凝血指标检测在肺癌诊断中的应用价值[J]. 癌症进展, 2019, 17(16): 1960-1962. https://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ201916026.htm

    TAN Y F, LIUL H, SUN J X. Application value of NSE, SCC-AG, CEA, CYFRA21-1 combined with coagulation index detection in the diagnosis of lung cancer[J]. Oncology Progress, 2019, 17(16): 1960-1962. https://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ201916026.htm
    [3]
    杨宇明, 段贵新, 王安生. lncRNA HOTAIR及肿瘤标志物联合检测与肺癌病理分期的相关性研究[J]. 中华全科医学, 2020, 18(10): 1652-1655. doi: 10.16766/j.cnki.issn.1674-4152.001584

    YANG Y M, DUAN G X, WANG A S. Correlation between lncRNA HOTAIR and tumor markers and pathological stage of lung cancer[J]. Chinese Journal of General Practice, 2020, 18(10): 1652-1655. doi: 10.16766/j.cnki.issn.1674-4152.001584
    [4]
    ROSENTHAL R, CADIEUX E L, SALGADO R, et al. Neoantigen-directed immune escape in lung cancer evolution[J]. Nature, 2019, 567(7749): 479-485. doi: 10.1038/s41586-019-1032-7
    [5]
    HAVEL J J, CHOWELL D. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy[J]. Nat Rev Can, 2019, 19(3): 133-150. doi: 10.1038/s41568-019-0116-x
    [6]
    陈冠璇, 宋现让. 肺癌PD-1/PD-L1免疫检查点治疗疗效预测标志物[J]. 中国肺癌杂志, 2018, 21(9): 697-702. https://www.cnki.com.cn/Article/CJFDTOTAL-FAIZ201809012.htm

    CHAN G X, SONG X R. Predictive markers for treating efficacy of PD-1/PD-L1 inhibitors in patients with lung cancer[J]. Chinese Journal of Lung Cancer, 2018, 21(9): 697-702. https://www.cnki.com.cn/Article/CJFDTOTAL-FAIZ201809012.htm
    [7]
    申宇嘉, 傅小龙. 非小细胞肺癌发生、发展过程中免疫微环境变化及其临床意义[J]. 中国癌症杂志, 2021, 31(11): 1115-1125. doi: 10.19401/j.cnki.1007-3639.2021.11.011

    SHAN Y J, FU X L. Research progress of immune contexture in tumorigenesis, progression and prognostic relevance of non-small cell lung cancer[J]. China Oncology, 2021, 31(11): 1115-1125. doi: 10.19401/j.cnki.1007-3639.2021.11.011
    [8]
    LI X C, LYU Q S, FENG Y H, et al. Interleukin-33, a potential cytokine expressed in tumor microenvironment involves in antitumor immunotherapy through facilitates CD8 T cells[J]. J Interferon Cytokine Res, 2018, 38(11): 491-499. doi: 10.1089/jir.2018.0069
    [9]
    MYERS J A, MILLER J S. Exploring the NK cell platform for cancer immunotherapy[J]. Nat Rev Clin Oncol, 2021, 182(2): 85-100.
    [10]
    VAN MONTFOOT N, BORST L, KORRER M J, et al. NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines[J]. Cell, 2018, 175(7): 1744-1755. doi: 10.1016/j.cell.2018.10.028
    [11]
    ZHANG W C, PAN Y L, GOU P H, et al. Effect of xanthohumol on Th1/Th2 balance in a breast cancer mouse model[J]. Oncol Rep, 2018, 39(1): 280-288.
    [12]
    LIN W, NIU Z Y, ZHANG H L, et al. Imbalance of Th1/Th2 and Th17/Treg during the development of uterine cervical cancer[J]. Int J Clin Exp Pathol, 2019, 12(9): 3604-3612.
    [13]
    李文军, 范桂虹, 杨明, 等. 不同分期肺癌患者血清外周血Th1、Th2细胞因子、IL-18水平变化及其预后研究[J]. 实用医院临床杂志, 2018, 15(5): 187-189. https://www.cnki.com.cn/Article/CJFDTOTAL-YYLC201805060.htm

    LI W J, FAN G H, YANG M, et al. Changes of serum Th1 and Th2 cytokines and IL-18 levels in patients with lung cancer at different stages and their correlation with prognosis[J]. Practical Journal of Clinical Medicine, 2018, 15(5): 187-189. https://www.cnki.com.cn/Article/CJFDTOTAL-YYLC201805060.htm
    [14]
    崔东, 许广辉, 贾忠伟, 等. NLR、VEGF、IL-6、TNF-α水平与非小细胞肺癌预后的相关性[J]. 现代肿瘤医学, 2019, 27(14): 2514-2518. https://www.cnki.com.cn/Article/CJFDTOTAL-SXZL201914021.htm

    CUI D, XU G H, JIA Z W, et al. Correlation between the levels of NLR, VEGF, IL-6, TNF-α, and the prognosis of NSCLC[J]. Journal of Modern Oncology, 2019, 27(14): 2514-2518. https://www.cnki.com.cn/Article/CJFDTOTAL-SXZL201914021.htm
    [15]
    JIA Y J, LI X F, ZHAO C, et al. Impact of serum vascular endothelial growth factor and interleukin-6 on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer[J]. Lung Can, 2018, 125(1): 22-28.
    [16]
    武道荣, 闫雪波, 方磊, 等. qSOFA评分联合IL-6 PCT CRP对ICU感染性休克患者病情及预后的评估价值[J]. 安徽医学, 2021, 42(8): 850-854. https://www.cnki.com.cn/Article/CJFDTOTAL-AHYX202108006.htm

    WU D R, YAN X B, FANG L, et al. The evaluation value of qSOFA score combined with serum IL-6, PCT and CRP levels for judgment and prognosis of ICU patients with septic shock[J]. Anhui Medical Journal, 2021, 42(8): 850-854. https://www.cnki.com.cn/Article/CJFDTOTAL-AHYX202108006.htm
    [17]
    吴晋楠, 陈建荣, 陈金亮, 等. 肺癌肿瘤微环境中白细胞介素的研究进展[J]. 临床肺科杂志, 2019, 24(12): 2280-2283. https://www.cnki.com.cn/Article/CJFDTOTAL-LCFK201912034.htm

    WU J N, CHEN J R, CHEN J L, et al. Research progress of interleukins in tumor microenvironment of lung cancer[J]. Journal of Clinical Pulmonary Medicine, 2019, 24(12): 2280-2283. https://www.cnki.com.cn/Article/CJFDTOTAL-LCFK201912034.htm
    [18]
    高斌成. 非小细胞肺癌外周血CD3+、CD4+等T淋巴细胞亚群水平及意义[J]. 临床肺科杂志, 2018, 23(1): 138-141. https://www.cnki.com.cn/Article/CJFDTOTAL-LCFK201801038.htm

    GAO B C. Expression and significance of CD3+, CD4+ T lymphocyte subsets in patients with non-small cell lung cancer[J]. Journal of Clinical Pulmonary Medicine, 2018, 23(1): 138-141. https://www.cnki.com.cn/Article/CJFDTOTAL-LCFK201801038.htm
    [19]
    林晓骥, 孙妮, 周晓海, 等. PD-1在弥漫性大B细胞淋巴瘤患者外周血CD4+T细胞和CD8+T细胞上的表达和临床意义[J]. 中国卫生检验杂志, 2018, 28(5): 556-558. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWJZ201805014.htm

    LIN X Y, SUN N, ZHOU X H, et al. Expression and clinical significance of PD-1 on CD4+ and CD+ T cells from the peripheral blood of patients with diffuse large B-cell lymphoma[J]. Chinese Journal of Health Laboratory Technology, 2018, 28(5): 556-558. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWJZ201805014.htm
    [20]
    王芸, 王郁阳, 姜曼, 等. 帕博利珠单抗对晚期非小细胞肺癌患者T淋巴细胞亚群的影响及疗效观测[J]. 中国肺癌杂志, 2021, 24(3): 182-187. https://www.cnki.com.cn/Article/CJFDTOTAL-FAIZ202103005.htm

    WANG Y, WANG Y Y, JIANG M, et al. Effect of pembrolizumab on T lymphocyte subsets in patients with advanced non-small cell lung cancer and its therapeutic effect[J]. Chinese Journal of Lung Cancer, 2021, 24(3): 182-187. https://www.cnki.com.cn/Article/CJFDTOTAL-FAIZ202103005.htm
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (364) PDF downloads(10) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return